US 11,053,295 B2
Peptides having effects of preventing or treating central nervous system diseases and pharmaceutical compositions for preventing or treating central nervous system diseases containing same as active ingredient
Je-Min Choi, Seoul (KR); and Sangho Lim, Seoul (KR)
Assigned to IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY), Seoul (KR)
Appl. No. 15/753,915
Filed by IUCF-HYU (INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY), Seoul (KR)
PCT Filed Aug. 19, 2016, PCT No. PCT/KR2016/009201
§ 371(c)(1), (2) Date Feb. 20, 2018,
PCT Pub. No. WO2017/034244, PCT Pub. Date Mar. 2, 2017.
Claims priority of application No. 10-2015-0117966 (KR), filed on Aug. 21, 2015; and application No. 10-2016-0105642 (KR), filed on Aug. 19, 2016.
Prior Publication US 2019/0202888 A1, Jul. 4, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. A61P 25/00 (2006.01); A61P 25/28 (2006.01); A61K 38/00 (2006.01); C07K 14/705 (2006.01); C12N 9/10 (2006.01); C07K 14/005 (2006.01); C07K 14/435 (2006.01)
CPC C07K 14/70521 (2013.01) [A61P 25/00 (2018.01); C07K 14/005 (2013.01); C07K 14/435 (2013.01); C12N 9/104 (2013.01); A61K 38/00 (2013.01); C07K 2319/10 (2013.01); C12N 2740/16022 (2013.01); C12N 2740/16033 (2013.01)] 8 Claims
 
1. A peptide comprising a fusion peptide of two or more fragments of cytoplasmic domain in a cytotoxic T lymphocyte antigen-4 (CTLA-4) protein, said fusion peptide comprising the amino acid sequence of SEQ ID NO: 4.